354 related articles for article (PubMed ID: 28330892)
1.
Brown-Elliott BA; Wallace RJ
J Clin Microbiol; 2017 Jun; 55(6):1747-1754. PubMed ID: 28330892
[TBL] [Abstract][Full Text] [Related]
2.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923878
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.
Vera-Cabrera L; Brown-Elliott BA; Wallace RJ; Ocampo-Candiani J; Welsh O; Choi SH; Molina-Torres CA
Antimicrob Agents Chemother; 2006 Dec; 50(12):4027-9. PubMed ID: 17015632
[TBL] [Abstract][Full Text] [Related]
5. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
Biedenbach DJ; Bouchillon SK; Johnson B; Alder J; Sahm DF
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1933-1939. PubMed ID: 27677280
[TBL] [Abstract][Full Text] [Related]
7.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
[TBL] [Abstract][Full Text] [Related]
8. Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.
Pfaller MA; Flamm RK; Jones RN; Farrell DJ; Mendes RE
Antimicrob Agents Chemother; 2016 Sep; 60(9):5393-9. PubMed ID: 27353270
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
10.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
[TBL] [Abstract][Full Text] [Related]
11. Comparison of
Brown Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0007921. PubMed ID: 33846136
[TBL] [Abstract][Full Text] [Related]
12. In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.
Zhang H; Hua W; Lin S; Zhang Y; Chen X; Wang S; Chen J; Zhang W
Infect Drug Resist; 2022; 15():4845-4852. PubMed ID: 36045871
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Efficacy of Novel Oxazolidinone Analogues against Nontuberculous Mycobacteria In Vitro.
Zhao W; Jiang Y; Bao P; Li Y; Tang L; Zhou Y; Zhao Y
Jpn J Infect Dis; 2015; 68(6):520-2. PubMed ID: 25971324
[TBL] [Abstract][Full Text] [Related]
14.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
15. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of in vitro activity of tedizolid and linezolid against Mycobacterium avium complex.
Marfil E; Ruiz P; Martínez-Martínez L; Causse M
J Glob Antimicrob Resist; 2022 Sep; 30():395-398. PubMed ID: 35863729
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.
Hatakeyama S; Ohama Y; Okazaki M; Nukui Y; Moriya K
BMC Infect Dis; 2017 Mar; 17(1):197. PubMed ID: 28270102
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of tedizolid against the Mycobacterium abscessus complex.
Compain F; Soroka D; Heym B; Gaillard JL; Herrmann JL; Dorchène D; Arthur M; Dubée V
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):186-189. PubMed ID: 29217419
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of Tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries.
Baek JY; Kang CI; Kim SH; Ko KS; Chung DR; Peck KR; Hsueh PR; Thamlikitkul V; So TM; Lee NY; Song JH;
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):218-20. PubMed ID: 27083121
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
